Kei Anastazia A, Filippatos Theodosios D, Elisaf Moses S
a Department of Internal Medicine, School of Medicine , University of Ioannina , Ioannina , Greece.
Expert Opin Drug Saf. 2016;15(4):559-69. doi: 10.1517/14740338.2016.1157164. Epub 2016 Mar 16.
In the light of the most recent and stricter dyslipidemia treatment guidelines, the need for combination hypolipidemic therapy is increasing. Ezetimibe plus simvastatin is available as a fixed dose therapy offering an efficient hypolipidemic treatment choice. Based on the positive results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial, the use of this drug combination is expected to increase in the next years.
This review discusses the current evidence regarding the safety of ezetimibe/simvastatin combination. Current evidence regarding possible associated side effects (musculoskeletal, gastrointestinal, endocrine, hematological, renal, ophthalmologic, allergic, malignancy) and drug interactions of this combination is thoroughly discussed.
Ezetimibe and simvastatin treatment, either as a single pill or the combined use of the individual compounds, offers limited additional risk compared with simvastatin monotherapy and comprises a safe and efficient choice for dyslipidemia treatment in high-risk and diabetic patients.
鉴于最新且更严格的血脂异常治疗指南，联合降脂治疗的需求日益增加。依折麦布加辛伐他汀作为一种固定剂量疗法，为降脂治疗提供了一种有效的选择。基于改善转归：Vytorin 疗效国际试验（IMPROVE-IT）的阳性结果，预计在未来几年这种药物组合的使用将会增加。
本综述讨论了关于依折麦布/辛伐他汀组合安全性的现有证据。对该组合可能相关的副作用（肌肉骨骼、胃肠道、内分泌、血液、肾脏、眼科、过敏、恶性肿瘤方面）及药物相互作用的现有证据进行了全面讨论。
依折麦布和辛伐他汀治疗，无论是制成单片制剂还是单独使用这两种化合物，与辛伐他汀单药治疗相比额外风险有限，对于高危和糖尿病患者的血脂异常治疗而言是一种安全有效的选择。
